EUVIMEDEUVIMED entdecken
Crossref

Recent Advances in Peroxisome Proliferator- Activated Receptor Science

Barry G. Shearer, William J. Hoekstra

Frontiers in Medicinal Chemistry - Online · 01.01.2005 · 2 (1) · 233-251

DOI: 10.2174/1567204052930970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Medicinal Chemistry - Online, erschienen am 01.01.2005. Verfasst von Barry G. Shearer und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The peroxisome proliferator-activated receptor (PPAR) family of nuclear receptors, a set of three receptor sub-types encoded by distinct genes, function as lipid sensors to regulate a broad range of genes in many metabolically active tissues. Synthetic PPAR agonists have exhibited therapeutic benefits in treating diabetes and cardiovascular diseases. The discovery of PPAR-specific ligands has led to significant advancement in our understanding of the structure of these receptor proteins and the molecular mechanism of their ligand-dependent activation. Herein, we present both recent progress in the functional analysis of these orphan receptors and the confirmation of the PPARs as molecular targets for the development of new medicines to treat human metabolic disease.

Zitieren

APA

Shearer, B. G., & Hoekstra, W. J. (2005). Recent Advances in Peroxisome Proliferator- Activated Receptor Science. Frontiers in Medicinal Chemistry - Online, 2(1), 233-251. https://doi.org/10.2174/1567204052930970

Vancouver

Shearer BG, Hoekstra WJ. Recent Advances in Peroxisome Proliferator- Activated Receptor Science. Frontiers in Medicinal Chemistry - Online. 2005;2(1):233-251. doi:10.2174/1567204052930970

BibTeX
@article{Shearer2005,
  author = {Shearer, Barry G. and Hoekstra, William J.},
  title = {Recent Advances in Peroxisome Proliferator- Activated Receptor Science},
  journal = {Frontiers in Medicinal Chemistry - Online},
  year = {2005},
  volume = {2},
  number = {1},
  pages = {233--251},
  doi = {10.2174/1567204052930970}
}
Kostenlos starten →